ALPORT SYNDROME, AUTOSOMAL RECESSIVE

Clinical trials for ALPORT SYNDROME, AUTOSOMAL RECESSIVE explained in plain language.

Never miss a new study

Get alerted when new ALPORT SYNDROME, AUTOSOMAL RECESSIVE trials appear

Sign up with your email to follow new studies for ALPORT SYNDROME, AUTOSOMAL RECESSIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug trial hopes to slow kidney damage in rare alport syndrome

Disease control Not yet recruiting

This study tests a drug called exaluren in 24 people aged 12 and older with Alport syndrome caused by specific genetic mistakes. The drug aims to improve kidney structure and reduce protein in urine. Participants first receive either exaluren or a placebo for 16 weeks, then every…

Matched conditions: ALPORT SYNDROME, AUTOSOMAL RECESSIVE

Phase: PHASE2 • Sponsor: Eloxx Pharmaceuticals, Inc. • Aim: Disease control

Last updated May 17, 2026 17:23 UTC

ALPORT SYNDROME, AUTOSOMAL RECESSIVE

Get alerted when new ALPORT SYNDROME, AUTOSOMAL RECESSIVE trials appear

New drug trial hopes to slow kidney damage in rare alport syndrome